莫匹罗星软膏联合0.05%地奈德乳膏治疗婴儿湿疹的临床研究

目的采用莫匹罗星软膏联合0.05%地奈德乳膏治疗婴儿湿疹,探索临床用药新方案。方法 126例患儿随机分为A、B组,每组63例患儿,A组先用莫匹罗星间隔2h后再用地奈德乳膏。B组单用地奈德乳膏。治疗7d、14d后观察疗效。结果治疗7d后A组和B组治疗效果有统计学差异(χ2=5.937,P<0.05)。治疗14d后A组和B组治疗效果有统计学差异(χ2=9.432,P<0.05)。14d总有效率A组95.24%高于B组84.12%。结论莫匹罗星软膏联合0.05%地奈德乳膏可提高婴儿湿疹疗效,缩短疗程。     

泳疗联合莫匹罗星治疗新生儿脓疱疮的效果观察

目的：探讨泳疗联合莫匹罗星治疗新生儿脓疱疮的效果。方法将确诊为脓疱疮的新生儿96例，随机分为观察组与对照组各48例。观察组采用泳疗联合莫匹罗星涂擦患处，2次/d；对照组采用青霉素20万 U 肌肉注射，2次/d。观察两组脓疱疮治疗效果。结果观察组治疗总有效率100％，平均消退时间（2．96±0．68）d；对照组治疗总有效率81．25％，平均消退时间（4．63±1．16）d ，差异有显著意义（ P＜0．05）结论泳疗联合莫匹罗星能有效治疗新生儿脓疱疮，并能显著缩短消退时间。     

莫匹罗星在动物致伤III类伤口愈合的疗效观察

目的针对动物致伤中III类伤口的高感染率,探讨如何减少感染、促进愈合。方法对我院急诊外科2010年1月1日至2012年12月31日动物致伤的川类伤口随机采用康复新液和莫匹罗星稀释液治疗,并分别采用开放引流及缝合治疗,按拆线日期进行伤口愈合评估,即伤口感染情况的对比研究。结果应用莫匹罗星组治愈率明显高于对照组,缝合与不缝合与用药相关,同种外用药物伤口的感染率无差异。结论莫匹罗星在动物致伤的III类伤口愈合中有促进作用,能减少感染,疗效显著,值得推荐。     

莫匹罗星软膏有关物质测定方法的建立

目的 建立莫匹罗星软膏有关物质HPLC分析方法。方法 采用Agilent Zorbax C8(250mm×4.6mm, 5μm)色谱柱,柱温：30℃,流动相：以pH5.7乙酸铵溶液-四氢呋喃不同比例线性梯度洗脱,流速：0.8mL/min,检测波长：240nm,进样量：20μL。结果 莫匹罗星及莫匹罗星杂质C、D、E分别在25~100μg/mL浓度范围内线性关系良好;定量限分别为0.016、0.047、0.019及0.020μg;杂质C、D和E的平均回收率分别为103.7%、98.6%和93.9%;重复性RSD均小于1.0%;酸、碱、高温、氧化、光照强制降解试验证明方法的专属性良好。结论 所建立的方法专属性、准确性及耐用性均良好,可用于莫匹罗星软膏有关物质的检测。     

龙珠软膏对C02激光术后创面修复作用的临床观察

目的观察龙珠软膏对二氧化碳激光术后创面修复作用的临床疗效。方法随机将82例二氧化碳激光术后患者分为两组各41例,治疗组外用龙珠软膏,对照组外用莫匹罗星软膏;比较两组术后疼痛持续时间、创面愈合时间、创面感染、创面愈合状况。结果治疗组疼痛持续时间、创面愈合时间明显短于对照组,两组感染发生率、色素沉着发生率、瘢痕发生率比较,差异均有统计学意义（P〈0．05）。结论龙珠软膏能缩短术后患者疼痛持续时间、创面愈合时间,预防创面感染,降低色素沉着及瘢痕形成的发生率,值得在激光术后应用。     

莫匹罗星辅助治疗婴儿湿疹182例分析

目的:观察莫匹罗星辅助治疗婴儿湿疹的效果。方法:回顾性分析2009年11月～2010年1月使用丁酸氢化可的松辅以莫匹罗星治疗婴儿湿疹182例的临床资料。结果:本组患儿182例,治疗组临床疗效与对照组比较差异有统计学意义(P<0.01)。结论:莫匹罗星辅助治疗婴儿湿疹该方法简单,无不良反应,值得临床推广应用。     

芒硝溶液外敷治疗化疗药物外漏的疗效观察

目的：观察芒硝溶液对肿瘤化疗药物外漏的治疗疗效。方法：选择经细胞学和病理学检查证实为晚期恶性肿瘤并在化疗时出现化疗药物外漏的患者48例,以外敷芒硝溶液组作为试验组（25例）,以外敷百多邦组作为对照组（23例）,观察和比较它们对化疗药物外漏的治疗疗效。结果：与对照组相比,试验组对化疗药物外漏有明显的治疗疗效。结论：外敷芒硝溶液能减轻化疗不良反应,辅助化疗顺利进行,改善晚期肿瘤患者的生活质量。     

Decreasing expander breast infection: A new drain care protocol

BACKGROUND:

Risk factors for expander reconstruction infection are well known. However, drain use as a risk factor for the development of infection is unclear.

OBJECTIVE:

To review a simple method for drain use to help reduce rates of infection in expander breast reconstruction.

METHODS:

Two hundred consecutive single-surgeon (JDM) immediate first-stage expander breast reconstructions were retrospectively reviewed. The records were reviewed for history and physical examination, intra-operative technique, perioperative management, adjuvant therapy, and outcome with respect to expander infection necessitating premature explantation within the first eight weeks. Infection was defined on clinical basis, with or without culture positivity. All expanders (Mentor, USA) were the same model (textured, port-integrated and biodimensional). Two consecutive series of reconstructions were then created. The first series included 177 reconstructions while the second series included 23 reconstructions. Unlike the first series, the second series introduced a protocol in which all reconstructions received mupirocin 2% cream to the drain sites and all drains were removed at the end of the first week. Additionally, in the second series, all expanders were secluded from direct in vivo contact with the closed suction drain either by the use of an intervening Alloderm sling (LifeCell Corporation, USA, 15 of 23 breasts) or by subdermally tunnelling the drain superficial to an adequate fatty subcutaneous layer (eight of 23 breasts).

RESULTS:

Patients who developed infection in the first series and all patients in the second series shared statistically the same level of aggregate risk factors (P=0.531). The infection rate (5.65%, 10 infections in 177 breasts) in the first series was statistically greater than in the second series (0%, 0 in 23 breasts, P=0.001).

CONCLUSIONS:

The present study found that percutaneous closed suction drains do serve as an increased risk for expander infection. However, early results indicate that in vivo protection of the expander with Alloderm or subdermal tunnelling, topical antibiotic ointment use and early drain removal may significantly reduce expander infection.     

泳疗联合莫匹罗星软膏治疗新生儿毒性红斑预防脓疱疹疗效分析

目的:分析采用泳疗配合莫匹罗星及常规护理治疗新生儿毒性红斑临床效果。方法:将112例患儿随机分为治疗组和对照组,对照组给予常规护理治疗,治疗组在常规治疗基础上配合泳疗及莫匹罗星治疗,观察分析其疗效。结果:治疗组总有效率为96.5%明显高于对照组76.7%(χ2=4.5P<0.05)。结论:泳疗联合莫匹罗星治疗毒性红斑并发脓疱疹疗效显著。     

莫匹罗星联合rhEGF治疗外伤性脊髓损伤患者并发压疮的疗效观察

目的:观察莫匹罗星联合重组人表皮生长因子(rhEGF)治疗外伤性脊髓损伤患者并发压疮的临床疗效。方法:将62例外伤性脊髓损伤并发压疮的患者随机分为2组,治疗组31例先将莫匹罗星软膏涂在伤口创面上,然后涂上rhEGF凝胶(厚度约2mm,宽度以超过创面2cm为宜);对照组31例仅采用rhEGF凝胶治疗,比较2组患者的疗效。结果:治疗组总有效率为94.3%,对照组为71.9%,2组疗效比较差异有统计学意义(P<0.05),且治疗组治愈时间和换药次数均显著少于对照组(P<0.05)。2组治疗过程中均未见不良反应发生。结论:莫匹罗星联合rhEGF治疗外伤性脊髓损伤患者并发压疮,临床疗效较好,安全性高。